Abstract: A method for producing a fatty acid polyoxyethylene methyl ether in which ethylene oxide is added to a fatty acid methyl ester component comprising, as a main component, a fatty acid methyl ester having a fatty acid residue of 18 to 22 carbon atoms, the addition being conducted in the presence of a composite metal oxide catalyst and at least one alcohol selected from the group consisting of diethylene glycol, ethylene glycol, propylene glycol, ethanol, methanol and isopropyl alcohol.

Abstract: Provided is a testing method for determining an oral indicator by which an oral indicator can be determined. The testing method for determining an oral indicator includes an image acquisition step of acquiring an ultrasonic image of an inside of an attached gingiva of a subject, using a measurement probe, an average brightness acquisition step of acquiring average brightness of the ultrasonic image, and an indicator determination step of determining an oral indicator of the subject by referring to the average brightness and a reference of an oral indicator.

Abstract: A liquid detergent of the present invention contains: component (a): a nonionic surfactant which contains compounds represented by the following formula (1) wherein an average value of m in formula (1) ranges from 5 to 20; and in which a ratio of the compound wherein R1 is a double bond-containing unsaturated hydrocarbon group is equal to or greater than 45% by mass with respect to a total amount of the component (a), and a ratio of the compound wherein R1 is an unsaturated hydrocarbon group having two or more double bonds is equal to or greater than 4% by mass with respect to a total amount of the compounds of formula (1) wherein R1 is an unsaturated hydrocarbon group; and component (b): an anionic surfactant. R1CO(EO)mOR2??(1) wherein R1 is a saturated or unsaturated hydrocarbon group having 15 to 17 carbon atoms; EO is an oxyethylene group; m is a positive integer; and R2 is an alkyl group having 1 to 3 carbon atoms.

Abstract: A coated ?-sulfofatty acid alkyl ester salt particle group containing ?-sulfofatty acid alkyl ester salt particles (A) and a zeolite particle group-containing coating component (B) with which the particles (A) are coated, in which the zeolite particle group is a zeolite particle group (b1) having a mean particle size of equal to or greater than 0.8 ?m and less than 3.8 ?m.

Abstract: Disclosed is an ethoxylation catalyst having a BET specific surface area of 40 to 150 m2/g and including calcium sulfate particles including at least one kind of compound selected from the group consisting of calcium sulfate 0.5 hydrate and type III anhydrous calcium sulfate.

Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.

Abstract: A detergent composition containing an ?-sulfo fatty acid alkyl ester salt and a fragrance composition, wherein the amount of the ?-sulfo fatty acid alkyl ester salt is from 1 to 30% by mass relative to the total mass of the detergent composition, the fragrance composition contains a fragrance (A) described below, and the amount of the fragrance (A) is from 0.07 to 0.5% by mass relative to the total mass of the detergent composition. Fragrance (A): a fragrance composed of at least one fragrance component selected from the group consisting of dihydromyrcenol, isobornyl acetate, ?-hexyl cinnamic aldehyde, lilial, tetrahydrolinalool, amyl salicylate, verdox, vertenex, tricyclodecenyl acetate, tricyclodecenyl propionate, Iso E Super and habanolide.

Abstract: The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.

Abstract: This liquid detergent contains an ?-sulfofatty acid ester salt (component (a)), an alkylbenzene sulfonate (component (b)), a polyoxyethylene alkyl ether sulfate (component (c)), and an alkanolamine (component (d)). The amount of the component (a) is 5% by mass or greater; the total amount of the component (b) and the component (c) is 5% by mass or greater; the total amount of the component (a), the component (b), and the component (c) is 10% by mass to 50% by mass, the mass ratio represented by (d)/(a) is 1/5 or greater, and the mass ratio represented by (a)/((b)+(c)) is 1 or less.

Abstract: A surfactant solution of the present invention includes a component (a): an ?-sulfonated fatty acid ester salt; a component (b): an alkanolamine; a component (c): an aromatic sulfonic acid; and a component (d): water, wherein the content of the component (a) is within a range from 30 to 45 mass %, the molar ratio represented by (b)/(a) is within a range from 0.05 to 0.5, and the molar ratio represented by (b)/(c) is within a range from 0.5 to 2.

Abstract: The invention provides a fatty acid alkyl ester sulfonate metal salt mixture of (a) a fatty acid alkyl ester sulfonate metal salt having an endothermic peak area at 50 to 130° C. of less than 50% relative to the whole endothermic peak area at 0 to 130° C. as measured on a differential scanning calorimeter, and (b) a fatty acid alkyl ester sulfonate metal salt having an endothermic peak area at 50 to 130° C. of 50% or more relative to the whole endothermic peak area at 0 to 130° C. as measured on a differential scanning calorimeter, with a ratio of (a) to (b) by mass of 95/5 or less. The mixture of the invention is excellent in anti-caking properties.

Abstract: A panaxadiol-containing composition, containing: panaxadiol; and at least one of sucrose fatty acid ester and lecithin.

Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.

Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.

Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.

Abstract: The present invention provides a treatment agent composition for fiber products capable of producing an exceptional odor-eliminating and odor-preventing effect against various odors. This treatment agent composition for fiber products comprises: (A) highly branched cyclic dextrin; (B) at least one compound selected from the group consisting of an amine compound having within each molecule one to three C10-26 hydrocarbon groups optionally split with an ester group or an amide group, a salt of the amine compound, and a quaternized form of the amine compound; and (C) at least one compound selected from (C-1)-(C-3) below: (C-1) a fatty acid expressed by RaCOOH (Ra is a fatty acid represented by a C8-35 alkyl or alkenyl group), (C-2) a silicone compound, and (C-3) an aliphatic alcohol represented by RbOH (Rb is an aliphatic alcohol represented by a C8-35 alkyl or alkenyl group).

Abstract: The object of the present invention is to provide a marker substance capable of determining a risk of hyperglycemia in vivo with high accuracy. The present invention provides the following: a marker peptide for determining the risk of hyperglycemia; an antibody or an aptamer bound to the marker peptide for determining the risk of hyperglycemia; a microarray wherein the antibody or the aptamer to be bound to the marker peptide for determining the risk of hyperglycemia has been immobilized onto a carrier; a method of determining the risk of hyperglycemia wherein an amount or the presence/absence of the marker peptide for determining the risk of hyperglycemia is measured in a biological sample collected from a subject; and a kit for determining the risk of hyperglycemia comprising the antibody or the aptamer, or the microarray.

Abstract: It is an object of the present invention to provide a composition containing lactoferrin and another component and having a prominent effect of promoting visceral lipolysis. That is, the present invention is a composition for promoting the lipolysis; a food product, a feedstuff or a pharmaceutical product including (A) lactoferrin and (B) one or more ingredients selected from the group consisting of a Durvillaea extract, raspberry ketone, an artichoke leaf extract, a rosemary extract, isoflavone, a grape seed extract, a pine bark extract, a Coleus forskohlii extract, and a cacao extract. Also provided is a method of giving the effect of promoting the lipolysis to the food product or the feedstuff by adding the component (A) and the component (B) for promoting the lipolysis to the food product or the feedstuff.

Abstract: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.

Abstract: It is an object of the present invention to provide a marker substance capable of accurately determining a risk of developing metabolic syndrome in vivo. That is, the present invention provides the followings: a marker peptide for determining the risk of developing the metabolic syndrome; an antibody or an aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome; a microarray in which the antibody or the aptamer bound to the marker peptide for determining the risk of developing the metabolic syndrome has been immobilized on a carrier; a method for determining the risk of developing the metabolic syndrome, comprising measuring an amount or the presence or absence of the marker peptide for determining the risk of developing the metabolic syndrome in a biological sample collected from a subject; and a kit for determining the risk of developing the metabolic syndrome, comprising the antibody or the aptamer or comprising the microarray.